tirzepatide discontinuation weight regain for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Weight regain after the withdrawal

That last distinction is not semantic it carries direct safety implications covered in detail here

consider if other first-line options are unsuitable Clinicians should initiate treatment at low doses, titrating gradually whilst monitoring for adverse effects such as sedation, dizziness, weight gain, or anticholinergic symptoms with amitriptyline

Ngoi ra cn c cc phn ng d ng nh kh th, tc ngc, kh nut hoc ni chuyn, st, pht ban, ni m ay, nga, Khi gp cc phn ng trn, bn cn n gp bc s c iu tr cc triu chng trn

During exendin-4 treatment, IL- 1b was transiently increased in normoglycemic mice and decreased in hyperglycemic mice